Abpro Holdings, Inc. is a biotechnology company. The Company is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration (AMD) and diabetic macular edema (DME). These antibodies are developed using the Companyâ€™s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patientâ€™s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. It plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	1.34M 1.16M 1.09M 999K 1.88M 128M 1.91M 12.75M 5M 63.97M 5.05M 4.94M 212M	P/E 2024	-2.41x	P/E 2025	-3.27x
Enterprise Value	1.42M 1.23M 1.15M 1.06M 2M 136M 2.02M 13.51M 5.3M 67.78M 5.35M 5.23M 225M	EV / Sales 2024	497x	EV / Sales 2025	-
Free-Float	83.91%	Yield 2024 *	-	Yield 2025	-

21/05	Abpro Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
16/04	Abpro Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
15/04	Abpro Holdings, Inc. Auditor Raises 'Going Concern' Doubt	CI
25/02	Abpro Holdings, Inc.(NasdaqCM:ABP) dropped from S&P TMI Index	CI
20/02	Abpro Holdings, Inc.(OTCPK:ABPO) dropped from NASDAQ Composite Index	CI
04/02	Abpro Holdings, Inc. Announces Board and Committee Resignations	CI
24/01	Abpro Holdings, Inc. Announces Board and Committee Changes	CI
17/01	Abpro Holdings, Inc. announced that it expects to receive $0.147 million in funding	CI
07/01	Abpro, Celltrion Say Solid Cancer Tumor Therapy Investigational New Drug Application Receives US FDA Clearance	MT
06/01	Abpro Holdings, Inc. and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72	CI
15/12	Abpro Holdings announces submission of an IND application to initiate a Phase 1 clinical trial of T cell engager ABP-102/CT-P72 for HER2-positive cancers	RE
15/12	Abpro Holdings, Inc. and Celltrion, Inc. Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T Cell Engager ABP-102/CT-P72 for HER2-Positive Cancers	CI
15/11	Abpro Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

15/01	Abpro’s Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference	AQ
06/01	Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72	AQ
15/12	Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers	AQ
09/12	Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives	AQ
05/11	Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABPRO CORPORATION	-.--%	-.--%	-	-	1.34M
LONZA GROUP AG	+0.90%	+0.21%	-0.74%	+13.87%	48B
REVOLUTION MEDICINES, INC.	+1.98%	+7.31%	+430.66%	+532.17%	41.13B
IQVIA HOLDINGS INC.	+3.44%	-2.84%	+29.17%	+8.81%	37.56B
BEONE MEDICINES AG	+1.40%	-0.89%	+7.63%	+61.93%	35.91B
CELLTRION, INC.	+2.42%	+7.27%	+14.90%	+44.79%	29.86B
ASCENDIS PHARMA A/S	-0.16%	-4.02%	-	-	16.12B
MEDPACE HOLDINGS, INC.	+2.20%	+2.94%	+35.92%	+127.15%	16.05B
EUROFINS SCIENTIFIC SE	+1.25%	+1.69%	+4.72%	+18.26%	13.76B
ICON PUBLIC LIMITED COMPANY	+4.25%	-9.28%	-0.78%	-35.46%	12.1B
Average	+1.77%	-2.15%	+65.18%	+96.44%	27.83B
Weighted average by Cap.	+1.91%	-1.29%	+85.86%	+120.78%

	2024	2025
Net sales	183K 158K 148K 136K 256K 17.4M 259K 1.74M 680K 8.7M 687K 672K 28.86M	-
Net income	-7.23M -6.26M -5.84M -5.37M -10.13M -688M -10.25M -68.57M -26.89M -344M -27.16M -26.56M -1.14B	-2.89M -2.5M -2.33M -2.15M -4.05M -275M -4.1M -27.42M -10.75M -138M -10.86M -10.62M -456M
Net Debt	478K 414K 386K 355K 670K 45.46M 677K 4.53M 1.78M 22.74M 1.8M 1.76M 75.38M	80K 69.24K 64.56K 59.41K 112K 7.61M 113K 759K 297K 3.81M 300K 294K 12.62M

Abpro Corporation Stock Nasdaq

Stocks

US0008501076

Biotechnology & Medical Research

Valuation: Abpro Corporation

Latest news : Abpro Corporation

Press Releases: Abpro Corporation

Other Biotechnology & Medical Research

Financials

Company Profile